A Study To Assess The Effect Of PF-03526299 On Lung Function Following An Allergen Challenge In Asthmatic Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

December 31, 2009

Study Completion Date

July 31, 2010

Conditions

Asthma

Interventions

DRUG

PF-03526299

Inhaled, two doses 4 hours apart

DRUG

Placebo

Inhaled, two doses 4 hours apart

DRUG

Fluticasone propionate

Inhaled

Trial Locations (2)

Pfizer Investigational Site, London

Pfizer Investigational Site, Manchester